Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Viral Infections of the Nervous System, Chronic Meningitis, and Prior Diseases, Progressive Multifocal Leukoencephalopathy
Adams & Victors Principles of Neurology, Chp 33, pg 767, Ropper, A.H.,et al, 2014
Progressive Multifocal Leukoencephalopathy: Prognosis and treatment
UpToDate, June, Koralnik, I.J.,et al, 2011
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007
Inflammatory Progressive Multifocal Leukoencephalopathy in Human Immunodeficiency Virus-Negative Patients
Ann Neurol 62:34-39, Huang,D.R.,et al, 2007
Characteristics and Antecedents of Progressive Multifocal Leukoencephalopathy in an Insured Population
Neurol 67:884-886, Eng,P.M.,et al, 2006
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Is JC Virus Latent in Brain?
Ann Neurol 29:433-434, Lipton,H.L., 1991
Implications of Progressive Multifocal Leukoencephalopathy and JC Virus for the Etiology of MS
Acta Neurol Scand 83:20-23, Stoner,G.L., 1991
Neurologic Manifestations of AIDS
Medicine 66:407-437, McArthur,J.C., 1987